# Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

> **NCT04551495** · PHASE2 · UNKNOWN · sponsor: **Jules Bordet Institute** · enrollment: 65 (estimated)

## Conditions studied

- Invasive Lobular Breast Carcinoma
- ER+ Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Entrectinib
- **DRUG:** Letrozole
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT04551495
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-14
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551495, "Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04551495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*